The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today ...

Deciphera Pharmaceuticals’ DCPH shares surged 74.3% in the past month after the cancer-focused, commercial-stage biopharmaceutical company announced entering into a definitive merger agreement with ...

"We've gotten to stage 1 and 2 on a global level, but in order to start recording sales at a quicker pace, we need to obtain a pipeline from outside. This acquisition is the first step in that ...

April 29 (Reuters) - Deciphera Pharmaceuticals (DCPH.O), opens new tab said on Monday Japan's Ono Pharmaceutical Co (4528.T), opens new tab will acquire the cancer drugmaker for $2.4 billion to expand ...

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

Deciphera Pharmaceuticals, a Waltham cancer biotech, said Monday it will be bought by Ono Pharmaceutical for $2.4 billon to expand the Japanese firm’s oncology portfolio and spur its growth in the ...

Deciphera Pharmaceuticals' stock has rallied 50% since October after positive trial data for its drug vimseltinib in the treatment of TGCT. Vimseltinib has the potential to make significant progress ...

Deciphera Pharmaceuticals Inc DCPH announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT) not amenable to surgery. The study met ...

More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...